Research and Markets: Crohn's Disease (CD) Therapeutics - The CD Therapeutics Market is Forecast to Show Increased Growth up to 2018

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/5cc599/crohns_disease_c) has announced the addition of GlobalData's new report "Crohn's Disease (CD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018" to their offering.

“Crohn's Disease (CD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018”

GlobalData, the industry analysis specialist, has released its new report, Crohn's Disease (CD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018. The report is an essential source of information and analysis on the global Crohn's Disease Therapeutics market. The report identifies the key trends shaping and driving the global Crohn's Disease Therapeutics market.

The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Crohn's Disease Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData has estimated that the global Crohn's Disease (CD) therapeutics market was worth $3.6 billion in 2010, which grew at a compound annual growth rate (CAGR) of 25.2% from $1.2 billion in 2005. This high growth rate, during the period 2005-2010, was primarily attributed to the launch of biologics such as Humira (adalimumab), Cimzia (certolizumab pegol) and Tysabri (natalizumab) and the increased uptake of the biologics Remicade (Infliximab) and Entocort EC (budesonide).

The CD therapeutics market is forecast to show moderate growth, at a CAGR of 2.6% for the next eight years, to reach $4.4 billion by 2018. This reduced growth will come as a result of the patent expiries of Remicade and Entocort EC and the subsequent launch of biosimilars in the forecast period. The CD therapeutics pipeline is strong, with first-in-class molecules in the late stage of development, which when launched are expected to off-set the generic incursion and drive the market.

Companies Mentioned:

• GlaxoSmithKline
• Johnson & Johnson
• Osiris Therapeutics, Inc.
• Takeda Pharmaceutical Company Limited

For more information visit http://www.researchandmarkets.com/research/5cc599/crohns_disease_c